Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 243

Results For "MIT"

4660 News Found

Roche introduces navify sample tracking for labs to track patient test samples
News | May 23, 2023

Roche introduces navify sample tracking for labs to track patient test samples

navify Sample Tracking is part of the navify Diagnostics portfolio, a set of digital solutions enabling labs to drive end-to-end operational excellence across care settings.


Zydus receives final approval from the USFDA for Ephedrine Sulfate Injection
Drug Approval | May 22, 2023

Zydus receives final approval from the USFDA for Ephedrine Sulfate Injection

Ephedrine Sulfate Injection USP, 50 mg/mL had annual sales of USD 52 mn in the United States


Eris Lifesciences posts consolidated Q4FY23 PAT at Rs. 65.41 Cr
News | May 22, 2023

Eris Lifesciences posts consolidated Q4FY23 PAT at Rs. 65.41 Cr

Eris Lifesciences has reported total income of Rs. 403.80 crores during the period ended March 31, 2023


Modi addresses 76th session of the World Health Assembly in Geneva virtually
News | May 22, 2023

Modi addresses 76th session of the World Health Assembly in Geneva virtually

India’s efforts are aimed at boosting health at the last mile


Croda signs supply deals with Amyris, BSI for vaccine adjuvants
News | May 21, 2023

Croda signs supply deals with Amyris, BSI for vaccine adjuvants

These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.


Abbott India posts Q4FY23 PAT at Rs. 231.42 Cr
News | May 20, 2023

Abbott India posts Q4FY23 PAT at Rs. 231.42 Cr

The company has reported total income of Rs. 1392.72 crores during the period ended March 31, 2023


Alkem Laboratories posts Q4 FY23 consolidated PAT slides to Rs. 70.98 Cr
News | May 20, 2023

Alkem Laboratories posts Q4 FY23 consolidated PAT slides to Rs. 70.98 Cr

The company has reported total income of Rs. 2971.27 crores during the period ended March 31, 2023


Strides Puducherry facility receives EIR  from USFDA
Drug Approval | May 20, 2023

Strides Puducherry facility receives EIR from USFDA

The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.


Granules India received ANDA approval for Venlafaxine ER capsules
Drug Approval | May 20, 2023

Granules India received ANDA approval for Venlafaxine ER capsules

Venlafaxine HCl extended-release capsules are indicated for the treatment of: Major Depressive Disorder


Moderna presents Phase 1/2 of MRNA-3927at 2023 ASGCT Meeting
Diagnostic Center | May 20, 2023

Moderna presents Phase 1/2 of MRNA-3927at 2023 ASGCT Meeting

First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement